Leishmania braziliensis is a parasitic protozoan that causes a skin infection known as cutaneous leishmaniasis. It is transmitted to humans through the bites of infected sandflies. The disease is prevalent in Latin America, with Brazil being one of the most affected countries. The treatment for this disease is challenging, and there is no vaccine available to prevent it. However, researchers have identified various immunodominant antigens that could help in the development of an effective vaccine.

Amastin-like Surface Protein:
Amastin-like surface protein is a protein found on the surface of Leishmania braziliensis. It plays a critical role in the parasite’s survival and virulence. Studies have shown that Amastin-like surface protein could be a potential vaccine candidate against cutaneous leishmaniasis.

Proliferating Cell Nuclear Antigen:
Proliferating cell nuclear antigen is a protein involved in DNA replication and repair. It is essential for the survival and growth of Leishmania braziliensis. Researchers have identified Proliferating cell nuclear antigen as a potential vaccine candidate against cutaneous leishmaniasis.

Surface Antigen-like Protein:
Surface antigen-like protein is another protein found on the surface of Leishmania braziliensis. It has been identified as a potential vaccine candidate against cutaneous leishmaniasis. Researchers have found that antibodies against Surface antigen-like protein can protect against the disease.

P21 Antigen Protein:
P21 antigen protein is a protein involved in cell cycle regulation. It is essential for the survival and growth of Leishmania braziliensis. Researchers have identified P21 antigen protein as a potential vaccine candidate against cutaneous leishmaniasis.

Surface Membrane Protein Gp46-like Protein:
Surface membrane protein Gp46-like protein is a protein found on the surface of Leishmania braziliensis. It is essential for the survival and growth of the parasite. Researchers have identified Surface membrane protein Gp46-like protein as a potential vaccine candidate against cutaneous leishmaniasis.

Immunodominant Antigen-Tc40:
Immunodominant antigen-Tc40 is a protein found in the flagellar pocket of Leishmania braziliensis. It has been identified as a potential vaccine candidate against cutaneous leishmaniasis. Researchers have found that antibodies against Immunodominant antigen-Tc40 can protect against the disease.

The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E. coli expression Vector), which are ready for production of the recombinant proteins.

The cDNA (complementary DNA) of Leishmania braziliensis can be used to produce recombinant antigens that have several applications, including:

Diagnosis of leishmaniasis: Recombinant antigens derived from Leishmania braziliensis cDNA can be used as diagnostic markers for the detection of leishmaniasis in clinical samples. These antigens can be used in diagnostic tests, such as ELISA, to detect antibodies produced by the host against the parasite.

Vaccine development: Recombinant antigens from Leishmania braziliensis cDNA can also be used to develop vaccines against leishmaniasis. These antigens can be used to stimulate the immune system to produce a protective response against the parasite, thereby preventing or reducing the severity of the disease.